Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSC-CRAd-S-pk7 in Recurrent High-Grade Gliomas
NCT05139056Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- May 2023
- Primary completion
- Feb 2028
- Modality
- Oncolytic Viruses, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NSC-CRAd-Survivin-pk7 in glioblastoma (GBM), sponsored by City of Hope. Primary endpoints: Incidence of adverse events at 30 days and Progression-free survival at 6 months. Started May 2023; status: recruiting.
02
Drugs
NSC-CRAd-Survivin-pk7
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05139056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139056.